Mural Oncology Plc2024财年第三财季实现净利润-31.76百万美元，同比增加38.07%

市场透视11-23

11月23日，Mural Oncology Plc（MURA.US）公布财报，公告显示公司2024财年第三财季净利润为-31.76百万美元，同比增加38.07%；其中营业收入为0.00美元，每股基本收益为-1.87美元。从资产负债表来看，Mural Oncology Plc（MURA.US）总负债29.13百万美元，其中短期债务5.44百万美元，资产负债比为0.07，流动比率为0.08。机构评级：...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2485713298?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-23 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2485713298","market":"us","top_or_hot":-1,"title":"Mural Oncology Plc2024财年第三财季实现净利润-31.76百万美元，同比增加38.07%","media":"市场透视","content":"<div>\n<p>11月23日，Mural Oncology Plc（MURA.US）公布财报，公告显示公司2024财年第三财季净利润为-31.76百万美元，同比增加38.07%；其中营业收入为0.00美元，每股基本收益为-1.87美元。从资产负债表来看，Mural Oncology Plc（MURA.US）总负债29.13百万美元，其中短期债务5.44百万美元，资产负债比为0.07，流动比率为0.08。机构评级：...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000035a24e4827&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mural Oncology Plc2024财年第三财季实现净利润-31.76百万美元，同比增加38.07%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMural Oncology Plc2024财年第三财季实现净利润-31.76百万美元，同比增加38.07%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-23 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000035a24e4827&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月23日，Mural Oncology Plc（MURA.US）公布财报，公告显示公司2024财年第三财季净利润为-31.76百万美元，同比增加38.07%；其中营业收入为0.00美元，每股基本收益为-1.87美元。从资产负债表来看，Mural Oncology Plc（MURA.US）总负债29.13百万美元，其中短期债务5.44百万美元，资产负债比为0.07，流动比率为0.08。机构评级：...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000035a24e4827&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MURA","symbol_name":"Mural Oncology","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000035a24e4827&s=b","article_id":"2485713298","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000035a24e4827&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2485713298","pubTimestamp":1732291216,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月23日，Mural Oncology Plc公布财报，公告显示公司2024财年第三财季净利润为-31.76百万美元，同比增加38.07%；其中营业收入为0.00美元，每股基本收益为-1.87美元。从资产负债表来看，Mural Oncology Plc总负债29.13百万美元，其中短期债务5.44百万美元，资产负债比为0.07，流动比率为0.08。机构评级：截至2024年11月23日，当前有4家机构对Mural Oncology Plc目标价做出预测，其中目标均价为16.00美元，其中最低目标价为13.00美元，最高目标价为18.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"MURA":"Mural Oncology"},"translate_title":"Mural Oncology Plc achieved net profit of-US $31.76 million in the third fiscal quarter of fiscal year 2024, a year-on-year increase of 38.07%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MURA":1},"content_text":"11月23日，Mural Oncology Plc（MURA.US）公布财报，公告显示公司2024财年第三财季净利润为-31.76百万美元，同比增加38.07%；其中营业收入为0.00美元，每股基本收益为-1.87美元。从资产负债表来看，Mural Oncology Plc（MURA.US）总负债29.13百万美元，其中短期债务5.44百万美元，资产负债比为0.07，流动比率为0.08。机构评级：截至2024年11月23日，当前有4家机构对Mural Oncology Plc目标价做出预测，其中目标均价为16.00美元，其中最低目标价为13.00美元，最高目标价为18.00美元。公司简介：Mural Oncology PLC 是一家临床阶段的肿瘤公司，其整个业务都集中在发现和开发可能有意义地改善癌症患者生活的免疫疗法。通过利用其在免疫细胞调节和蛋白质工程方面的核心竞争力，该公司开发了一系列新颖的研究性细胞因子疗法，旨在解决各种癌症患者未满足的需求。其候选产品Nemvaleukin是一种在研的、工程化的白细胞介素-2细胞因子，旨在捕获和扩大高剂量重组人IL - 2的治疗益处，同时减轻其标志性毒性。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485713298"}